SCHEMBL2598740

SCHEMBL2598740

Nc1nc(N)c(Cc2ccc3[nH]ccc3c2)c(Cc2ccc3[nH]ccc3c2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
DHFR P00374 8/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP2D6 P10635 1/20 0.39
ATM Q13315 1/20 0.39
F7 P08709 1/20 0.39
LTA4H P09960 1/20 0.39
F3 P13726 1/20 0.39
AHR P35869 1/20 0.39
NR4A2 P43354 1/20 0.39
BACE1 P56817 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
REN P00797 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2598555 0.89 BACE1 (0.49) DHFRALDH1A1CYP2D6ATMAHR
SCHEMBL16494968 0.84 CYP17A1 (0.39) CYP17A1CYP11B1CYP11B2F7LTA4H
SCHEMBL27916591 0.82 CYP17A1 (0.39) CYP17A1CYP11B1CYP11B2ALDH1A1CYP2D6
SCHEMBL16495337 0.80 ALDH1A1 (0.46) DHFRALDH1A1CYP2D6ATMADORA3
SCHEMBL2598691 0.79 KDM1A (0.42) CYP17A1CYP11B1CYP11B2BACE1ADORA3
SCHEMBL16494934 0.78 DHFR (0.39) DHFRALDH1A1CYP2D6ATM
SCHEMBL2598585 0.78 CYP2A6 (0.45) DHFRALDH1A1CYP2D6ATM
SCHEMBL6950768 0.76 CYP17A1 (0.39) CYP17A1CYP11B1CYP11B2CYP2D6F7
SCHEMBL16339192 0.75 DHFR (0.57) DHFR
SCHEMBL4230435 0.75 REN (0.50) ALDH1A1CYP2D6ATMREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571867-B1 NOVEL PYRIMIDINE DERIVATIVES NOVIGA RES AB (SE) 2015-11-04 EP claimed
US-20130089518-A1 NOVEL PYRIMIDINE DERIVATIVES CHEMILIA AB (SE) 2013-04-11 US claimed
EP-2571867-A1 NOVEL PYRIMIDINE DERIVATIVES Chemilia AB (SE) 2013-03-27 EP claimed
EP-2395001-A1 Novel pyrimidine derivatives Chemilia AB (SE) 2011-12-14 EP claimed
WO-2011144742-A1 NOVEL PYRIMIDINE DERIVATIVES CHEMILIA AB (SE) 2011-11-24 WO claimed
EP-2571867-B1 NOVEL PYRIMIDINE DERIVATIVES NOVIGA RES AB (SE) 2015-11-04 EP disclosed
US-8927547-B2 Pyrimidine derivatives NOVIGA RESEARCH AB (SE) 2015-01-06 US disclosed
CN-103003264-B Novel pyrimidine derivatives CHEMILIA AB 2014-08-06 CN disclosed
US-20130089518-A1 NOVEL PYRIMIDINE DERIVATIVES CHEMILIA AB (SE) 2013-04-11 US disclosed
EP-2571867-A1 NOVEL PYRIMIDINE DERIVATIVES Chemilia AB (SE) 2013-03-27 EP disclosed
EP-2395001-A1 Novel pyrimidine derivatives Chemilia AB (SE) 2011-12-14 EP disclosed
WO-2011144742-A1 NOVEL PYRIMIDINE DERIVATIVES CHEMILIA AB (SE) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130089518-A1 NOVEL PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP CYP17A1 3986/4885CYP11B1 3420/4885CYP11B2 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.